Total debt climbed from $80.5M in 2025Q2 to $133.9M in 2026Q3, and the debt-to-equity ratio of 0.62 appears to reflect equity rebuilt through a single recognition event rather than any reduction in absolute leverage.
MeiraGTx Holdings plc (MGTX) balance sheet — 10-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Total Current Assets | 242.35M | 91.76M | 123.52M | 159.62M | 154.34M | 183.24M | 272.58M | 268.98M | 74.65M | 11.48M | 19.09M |
| Cash & Short-Term Investments | 184.65M | 65.93M | 103.66M | 129.57M | 115.52M | 137.7M | 209.52M | 227.23M | 68.08M | 8.55M | 17.48M |
| Cash Only | 184.65M | 65.93M | 103.66M | 129.57M | 115.52M | 137.7M | 209.52M | 227.23M | 68.08M | 8.55M | 17.48M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 29.56M | 18.29M | 10.63M | 23.41M | 29.02M | 35.02M | 55.41M | 37.11M | 0 | 0 | 0 |
| Days Sales Outstanding | 24.99 | 82 | 116.57 | 609.72 | 665.41 | 339.02 | 1.3K | 1.02K | - | - | - |
| Inventory | 0 | 0 | 385K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | 5.91 | - | - | - | - | - | - | - | - |
| Other Current Assets | 24.31M | 1.53M | 2.02M | 1.02M | 1.67M | 2.42M | 564.44K | 170.59K | 4.63M | 965.23K | 400.96K |
| Total Non-Current Assets | 169.35M | 152.67M | 146.23M | 167.12M | 163.9M | 136.92M | 91.12M | 54.91M | 22.24M | 14.38M | 3.46M |
| Property, Plant & Equipment | 129.86M | 141.93M | 135.65M | 156.24M | 154.09M | 126.29M | 87.12M | 52.86M | 22.01M | 14.26M | 3.02M |
| Fixed Asset Turnover | 2.96x | 0.57x | 0.25x | 0.09x | 0.10x | 0.30x | 0.18x | 0.25x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 17K | 578K | 821K | 1.12M | 2.08M | 2.57M | 2.97M | 777.65K | 0 | 0 | 0 |
| Long-Term Investments | 89.33M | 6.75M | 6.75M | 6.77M | 6.33M | 6.66M | 0 | 123.38K | 123.38K | 123.38K | 444.84K |
| Other Non-Current Assets | 3.47M | 3.41M | 3.01M | 3M | 1.4M | 1.4M | 1.03M | 1.15M | 105.08K | 0 | 0 |
| Total Assets | 411.69M | 244.43M | 269.75M | 326.74M | 318.24M | 320.16M | 363.7M | 323.89M | 96.89M | 25.85M | 22.55M |
| Asset Turnover | 1.24x | 0.33x | 0.12x | 0.04x | 0.05x | 0.12x | 0.04x | 0.04x | - | - | - |
| Asset Growth % | 216.62% | -9.39% | -17.44% | 2.67% | -0.6% | -11.97% | 12.29% | 234.27% | 274.77% | 14.65% | - |
| Total Current Liabilities | 52.4M | 122.56M | 60.78M | 67.08M | 82.07M | 68.13M | 54.15M | 49.2M | 15.5M | 21.4M | 6.04M |
| Accounts Payable | 10.91M | 10.07M | 23.59M | 16.04M | 16.62M | 15.35M | 7.13M | 3.76M | 3.04M | 7.06M | 1.47M |
| Days Payables Outstanding | 262.86 | 758.64 | 361.85 | - | - | - | - | - | 541 | 3.79K | 2.21K |
| Short-Term Debt | 0 | 24.65M | 0 | 0 | 0 | 0 | 2.58M | 1.67M | 0 | 1.44M | 0 |
| Deferred Revenue (Current) | 14.46M | 1.78M | 4.83M | 2.93M | 15.12M | 21.82M | 23.54M | 25.68M | 11.99M | 10.19M | -6.01K |
| Other Current Liabilities | 16.28M | 63.09M | 12.1M | 41.28M | 16.23M | 6.03M | 17.09M | 11.23M | -5.82M | 2.68M | 1.96M |
| Current Ratio | 4.62x | 0.75x | 2.03x | 2.38x | 1.88x | 2.69x | 5.03x | 5.47x | 4.82x | 0.54x | 3.16x |
| Quick Ratio | 4.62x | 0.75x | 2.03x | 2.38x | 1.88x | 2.69x | 5.03x | 5.47x | 4.82x | 0.54x | 3.16x |
| Cash Conversion Cycle | -237.87 | - | -239.38 | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 144.07M | 127.67M | 141.14M | 121.49M | 118.43M | 66.64M | 70.99M | 83.89M | 336.48K | 51.82M | 33.65M |
| Long-Term Debt | 121.9M | 49.69M | 73.22M | 72.12M | 71.03M | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 41.67M | 11.46M | 7.52M | 12.95M | 17.33M | 20.36M | 19.67M | 21.5M | 7.1K | 34.3K | 5.46K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 186K | 196K | 213.72K | 195.05K | -201.26K | -266.29K | -588.49K |
| Other Non-Current Liabilities | 1.13M | 1.4M | 2.82M | 2.4M | 2.44M | 3.03M | 1.81M | 1.65M | 329.38K | 51.78M | 33.64M |
| Total Liabilities | 196.47M | 250.22M | 201.92M | 188.57M | 200.5M | 134.76M | 125.14M | 133.09M | 15.84M | 73.22M | 39.69M |
| Total Debt | 133.85M | 88.69M | 84.8M | 89.26M | 92.25M | 23.73M | 22.25M | 23.18M | 34.3K | 1.51M | 11.47K |
| Net Debt | -50.8M | 22.75M | -18.86M | -40.3M | -23.27M | -113.97M | -187.27M | -204.05M | -68.05M | -7.04M | -17.47M |
| Debt / Equity | 0.62x | - | 1.25x | 0.65x | 0.78x | 0.13x | 0.09x | 0.12x | 0.00x | - | - |
| Debt / EBITDA | 0.70x | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.26x | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | 26.25x | -8.36x | -10.14x | -5.34x | -25.21x | -275.25x | -415.60x | -1125.19x | -2336.42x | -739.21x | -788.70x |
| Total Equity | 215.22M | -5.79M | 67.83M | 138.18M | 117.74M | 185.4M | 238.56M | 190.8M | 81.06M | -47.37M | -17.14M |
| Equity Growth % | 7436.4% | -108.54% | -50.91% | 17.36% | -36.5% | -22.28% | 25.03% | 135.39% | 271.14% | -176.36% | - |
| Book Value per Share | 2.22 | -0.07 | 0.97 | 2.45 | 2.61 | 4.20 | 6.32 | 5.75 | 4.28 | -5.53 | -0.89 |
| Total Shareholders' Equity | 215.08M | -5.79M | 67.83M | 138.18M | 117.74M | 185.4M | 238.56M | 190.8M | 81.06M | -47.37M | -17.14M |
| Common Stock | 3K | 3K | 3K | 2K | 2K | 2K | 1.72K | 1.43K | 1.06K | 342 | 342 |
| Retained Earnings | -753.03M | -816.22M | -702.02M | -554.23M | -470.2M | -340.59M | -261.03M | -203.04M | -148.29M | -65.42M | -34.38M |
| Treasury Stock | -18.19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 3.23M | 2.41M | -3.72M | -1.44M | 6.05M | -2.67M | -4.9M | -1.79M | 293.67K | -2.02M | -661.11K |
| Minority Interest | 140K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying MGTX stock.
As of 2025, MeiraGTx Holdings plc (MGTX) had total assets of $244.4M including $91.8M in current assets.
MeiraGTx Holdings plc (MGTX) carries total debt of $88.7M, offset by $65.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
MeiraGTx Holdings plc (MGTX) has total shareholders' equity (book value) of $-5.8M ($-0.07 book value per share). Book value represents the net worth of the company belonging to common stock holders.
MeiraGTx Holdings plc (MGTX) reported a current ratio of 0.75x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Thin cash cushion against burn
Metrics are mathematically derived from official filings.
Balance Sheet Swinging Between Recapitalization Cycles
Based on reported figures, MGTX's equity swung from $215.6M in 2026Q2 to negative $58.1M in 2026Q1, a reversal that appears driven by deferred revenue recognition and accumulated deficit rather than sustained operating strength. Total liabilities jumped to $302.8M in the same quarter.
The sharp equity contraction between 2026Q2 and 2026Q1 suggests that the balance sheet is highly sensitive to the timing of partner payments and milestone accounting. Retained earnings remain deeply negative at roughly -$753.0M, indicating that cumulative losses continue to erode the capital base. Investors should monitor whether the 2026Q3 rebound in equity proves durable or simply reflects another lumpy recognition event.
Debt Rising Faster Than Cash Generation
According to reported quarterly figures, total debt climbed from $80.5M in 2025Q2 to $133.9M in 2026Q3, while the debt-to-equity ratio fell to 0.62 only because equity was rebuilt, not because leverage was reduced in absolute terms.
Debt has increased by roughly two-thirds over the observed period, which may indicate growing reliance on borrowed capital to fund clinical operations. The apparent improvement in D/E is largely an artifact of equity recovery from a negative base, so it should not be read as deleveraging. Refinancing terms and maturity profile are not disclosed in the supplied data, warranting further investigation.
Cash Cushion Thin Relative to Operating Burn
Based on EDBL's reported figures, cash fell to $14.8M in 2025Q3 before recovering to $184.7M in 2026Q3, a volatile path that leaves the company's runway dependent on episodic inflows rather than a stable reserve.
The current ratio moved from 0.22 to 4.62 over the period, a swing that reflects the timing of current liabilities and deferred revenue more than structural liquidity improvement. With quarterly operating losses frequently in the range of $40M to $50M, the 2026Q3 cash balance may represent only a few quarters of burn. Investors should treat the recent cash build as contingent on partner timing rather than assured operating capacity.
Fixed Asset Base Anchors an Asset-Light Story
As reported in financial statements, net PP&E held relatively steady between $129.9M and $144.5M across the period, forming the dominant non-current asset while goodwill has nearly vanished to $17.0K in 2026Q3.
The stable PP&E base reflects the vertically integrated manufacturing footprint, which suggests the business is more asset-heavy than typical gene therapy peers. Goodwill erosion from $969.0K to $17.0K indicates minimal acquisition-related intangible risk, which is a positive for balance sheet quality. The key question is whether this fixed base can be productively utilized once clinical programs move toward commercial scale.
Deferred Revenue Signals Milestone Dependence
According to recent SEC filings, deferred revenue rose from $57.3M in 2024Q2 to $66.9M in 2025Q4 before collapsing to $16.8M in 2026Q3, suggesting partner-recognized obligations are being worked down rather than replenished.
The sharp decline in deferred revenue from roughly $67M to $16.8M implies that a large portion of previously collected partner funding has been recognized into income. This pattern may indicate that near-term revenue visibility is limited unless new collaboration milestones are secured. Investors should monitor future deferred revenue balances as a leading indicator of whether recognized income will persist.
Equity Rebound May Reflect Accounting Timing
Based on reported figures, the swing from negative equity of -$58.1M to positive $215.1M within two quarters appears more consistent with a single large recognition event than with a fundamental improvement in capital structure.
Headline equity recovery could mislead analysts into assuming the balance sheet has been repaired, when accumulated deficit of roughly -$753.0M remains the dominant force. The rebound coincides with a drop in deferred revenue, suggesting obligations were converted into recognized income rather than new capital being raised. Investors should avoid extrapolating the 2026Q3 equity level as a stable baseline.